Syntara Ltd
ASX:SNT
Syntara Ltd
Depreciation & Amortization
Syntara Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Syntara Ltd
ASX:SNT
|
Depreciation & Amortization
-AU$234k
|
CAGR 3-Years
58%
|
CAGR 5-Years
38%
|
CAGR 10-Years
27%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Depreciation & Amortization
-AU$59.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Depreciation & Amortization
-AU$72.6k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-114%
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Depreciation & Amortization
-AU$6.2m
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Syntara Ltd
Glance View
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
See Also
What is Syntara Ltd's Depreciation & Amortization?
Depreciation & Amortization
-234k
AUD
Based on the financial report for Jun 30, 2024, Syntara Ltd's Depreciation & Amortization amounts to -234k AUD.
What is Syntara Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
27%
Over the last year, the Depreciation & Amortization growth was 87%. The average annual Depreciation & Amortization growth rates for Syntara Ltd have been 58% over the past three years , 38% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet